Company Name Neurotrack
Mailing Address 120 Hawthorne Ave. Palo Alto, CA 94301
Company Description Neurotrack’s technology can diagnose the onset of Alzheimer’s Disease three to four years before symptoms occur. Based on ground-breaking research, it enables pharmaceutical companies and researchers to recruit qualified candidates for clinical trials, and more effectively measure drug efficacy, speeding up drug discovery and development.
Proceeds Purposes The funds will be used to further develop and commercialize the company’s breakthrough technology, a visual cognitive test sensitive to damage in brain regions first impacted by Alzheimer’s disease.